Purification of biologically active peptides from milk

• US 6,268,487 B1
• Filed: 05/13/1996
• Issued: 07/31/2001
• Est. Priority Date: 05/13/1996
• Status: Expired due to Term

• Current Assignee: LFB USA, Inc. (Agence des Participations de l’Etat)
• Original Assignee: Genzyme Transgenics Corporation
• Inventors: Hayes, Michael L., Kutzko, Joseph P., Sherman, Lee T.
• Primary Examiner(s): CELSA, BENNETT M
• Application Number:
  US08/648,235
• Time in Patent Office: 1,905 Days
• Field of Search: 530/414, 530/412, 530/413, 530/416, 530/832, 435/69.1, 800/DIG.1
• US Class Current: 530/414
• CPC Class Codes: A23J 1/20 from milk, e.g. casein curds or cheese A23C; from whey
• CPC Class Codes: C07K 1/36 by a combination of two or more processes of different types
• CPC Class Codes: Y10S 530/832 Milk; colostrum

Abstract

A method of separating a soluble milk component from milk is disclosed. The method involves the use of tangential flow filtration across a membrane to form a retentate and a permeate, combining the permeate with the original milk sample, and repeating this procedure until the milk has been sufficiently purified. Preferably, the milk is combined with a chelating agent, such as EDTA, to improve the purification efficiency. This procedure is advantageously employed with milk from transgenic animals which have been genetically altered to express exogenous proteins, such as therapeutic proteins, in their milk.

Claims

1. A method of separating an exogenous component from a milk sample, comprising:

a) subjecting the milk sample containing at least one of the following;

fat, casein micelles, somatic cells or particulate matter, to tangential flow filtration across a membrane of sufficient porosity to form a retentate and a permeate comprising the exogenous component;

b) subjecting the permeate to a chromatography capture device to remove the exogenous component and providing an effluent;

c) combining the effluent with the retentate; and

d) repeating Steps a) through c) at least once and until the exogenous component is free of fat, casein micelles, somatic cells or particulate matter, and wherein the recovery of the exogenous component is 75-90%.

2. The method of claim 1 wherein the milk or milk fraction is combined with a chelating agent in an amount sufficient to reduce milk clumping and to improve passage through the filtration membrane.

3. The method of claim 1 wherein the component is a peptide or protein.

4. The method of claim 3 wherein the protein is selected from the group consisting of glycoproteins, immunoglobulins, peptides, hormones, enzymes, serum proteins, milk proteins, cellular proteins, soluble receptors and industrial enzymes.

5. The method of claim 4 wherein the protein is selected from the group consisting of alpha-1 proteinase inhibitor, alkaline phosphatase, angiogenin, antithrombin III, chitinase, extracellular superoxide dismutase, Factor VIII, Factor IX, Factor X, fibrinogen, glucocerebrosidase, glutamate decarboxylase, human serum albumin, insulin, myelin basic protein, lactoferrin, lactoglobulin, lysozyme, lactalbumin, proinsulin, soluble CD4, component and complexes of soluble CD4, tissue plasminogen activator and a variant thereof.

6. The method of claim 1 wherein tangential flow filter has a pore size in the range from 0.1 to 1,000 nanometers.

7. The method of claim 1 wherein bacteria, mycoplasma, viruses, prion particles and other microbial contaminants present in the raw milk are removed.

8. The method of claim 2 wherein the chelating agent is selected from the group consisting of EDTA, EGTA and citrate.

9. The method of claim 8 wherein the chelating agent is added to a final concentration range from 1 to 500 millimolar.

10. The method of claim 1 wherein the milk is obtained from a lactating non-human mammal selected from the group comprising transgenic mammals and transomic mammals.

11. The method of claim 10 wherein the milk is obtained from a transgenic cow, goat, pig, rabbit, mouse, rat or sheep.

12. The method of claim 8 wherein the chelating agent is EDTA.

13. The method of claim 12 wherein the EDTA is added to a final concentration of about 20 to 50 millimolar.

14. The method of claim 1 wherein the chromatography capture device is an affinity chromatograhy capture device.

15. The method of claim 14 wherein the affinity chromatography capture device is selected from the group consisting of heparin column, Protein A column or Protein G column.

16. The method of claim 14 wherein the chromatography capture device is an ion exchange chromatography capture device.